Lincoln Pharmaceuticals Posts ₹1.63 Billion Consolidated Revenue and ₹199.8 Million Net Profit in September Quarter

Lincoln Pharmaceuticals Shows Resilient Growth in Q2 with Strong Revenue and Profitability

Lincoln Pharmaceuticals Ltd. announced its consolidated financial results for the quarter ended September 2025, posting revenue from operations of ₹1.63 billion (₹163 crore). The company recorded a net profit of ₹199.8 million (₹19.98 crore), highlighting consistent earnings generation amid ongoing market challenges.

The company's ability to sustain revenue and profitability is attributed to its diversified product portfolio, focused cost management, and strengthening market presence. EBITDA margins remain firm, supporting bottom-line growth.

While revenue growth was moderate, Lincoln continues to focus on expanding its therapeutic offerings and improving operational efficiencies to capitalize on emerging opportunities. The company also maintains prudent financial discipline to support sustainable growth.

Investors and analysts view Lincoln’s performance positively, considering the stable cash flows and commitment to innovation in formulations and drug delivery technologies.

Key Highlights:

Consolidated revenue from operations: ₹1.63 billion for September quarter.

Net profit stands at ₹199.8 million, reflecting steady earnings.

Robust cost management and diversified portfolio aid performance.

EBITDA margins remain stable, underlining operational efficiency.

Continued focus on product innovation and market expansion.

Positive investor sentiment driven by consistent financial discipline.

Source: Moneycontrol, Business Standard, NSE India (2025)